<drug type="biotech" created="2016-12-30" updated="2017-03-04">
  <drugbank-id primary="true">DB13161</drugbank-id>
  <name>Nusinersen</name>
  <description>An antisense oligonucleotide that induces SMN protein expression, it was approved by the U.S. FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.</description>
  <cas-number>1258984-36-9</cas-number>
  <unii>5Z9SP3X666</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <title>FDA label</title>
        <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf</url>
      </link>
      <link>
        <title>CENTER FOR DRUG EVALUATION AND RESEARCH </title>
        <url>http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000ClinPharmR.pdf</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>Nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients</indication>
  <pharmacodynamics>Autopsy samples from patients (n=3) had higher levels of SMN2 messenger ribonucleic acid (mRNA) containing exon 7 in the thoracic spinal cord compared to untreated SMA infants.&#13;
Cardiac Electrophysiology: In 121 patients with spinal muscular atrophy who received either nusinersen or sham-control, QTcF values &gt;500 ms and change from baseline values &gt;60 ms were observed in 5% of patients receiving nusinersen. Compared to the sham-control, there was no increase in the incidence of cardiac adverse reactions associated with delayed ventricular repolarization in patients treated with nusinersen. </pharmacodynamics>
  <mechanism-of-action>Nusinersen is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, nusinersen was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein. &#13;
Nusinersen acts to replace the SMN protein deficit which causes SMA, by increasing the splicing efficiency of the SMN2 pre- mRNA. More specifically, nusinersen in an 18-mer 2’-MOE phosphorothioate antisense oligonucleotide that acts as a splice-altering oligonucleotide. Nusinersen was designed to pair with a specific target sequence on the SMN2 pre-mRNA to displace heterogeneous ribonucleoproteins (hnRNPs) at the intronic splice silencing site-1 (ISS-1) between exons 7 and 8 to allow for more complete translation of SMN protein from the paralogous gene SMN2.&#13;
Further reinforcing this concept, SMA phenotype is closely tied to SMN2 copy number. SMN2 serves to produce SMN protein, however at a greatly reduced rate because of differential splicing caused by the binding of the hnRNPs at the ISS-1.</mechanism-of-action>
  <toxicity>Single injection to adult monkeys produced apparent acute neurological impairment. </toxicity>
  <metabolism>Nusinersen is metabolized via exonuclease (3’- and 5’)-mediated hydrolysis and is not a substrate for, or inhibitor or inducer of CYP450 enzymes. </metabolism>
  <absorption>Intrathecal injection of nusinersen into the cerebrospinal fluid (CSF) allows it to be distributed from the CSF to the target central nervous system (CNS) tissues. Following intrathecal administration, trough plasma concentrations of nusinersen were relatively low, compared to the trough CSF concentration. Median plasma Tmax values ranged from 1.7 to 6.0 hours. Mean plasma Cmax and AUC values increased approximately dose-proportionally up to a dose of 12 mg. </absorption>
  <half-life>CSF: 135-177 days&#13;
Plasma: 85 days</half-life>
  <protein-binding>CSF: &lt; 25% &#13;
Plasma: &gt;94%</protein-binding>
  <route-of-elimination>Excreted by the kidney as chain-shortened oligonucleotides, which are not considered pharmacologically active.&#13;
 </route-of-elimination>
  <volume-of-distribution>CSF: 0.4 L &#13;
Plasma: 29 L</volume-of-distribution>
  <clearance>Slow clearance is observed</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Spinraza</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code>64406-058</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2.4 mg/mL</strength>
      <route>Intrathecal</route>
      <fda-application-number>NDA209531</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Spinraza</name>
      <ingredients>Nusinersen</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleotides</category>
      <mesh-id>D009711</mesh-id>
    </category>
    <category>
      <category>Polynucleotides</category>
      <mesh-id>D011119</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intrathecal</route>
      <strength>2.4 mg/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Nusinersen</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes>
    <enzyme position="1">
      <id>BE0003239</id>
      <name>Exonuclease</name>
      <organism>Enterobacteria phage lambda</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P03697" source="Swiss-Prot">
    <name>Exonuclease</name>
    <general-function>Metal ion binding</general-function>
    <specific-function>Facilitates phage DNA recombination through the double-strand break repair (DSBR) and single-strand annealing pathways. Also important for the late, rolling-circle mode of lambda DNA replication.</specific-function>
    <gene-name>exo</gene-name>
    <locus/>
    <cellular-location/>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>5.41</theoretical-pi>
    <molecular-weight>25908.385</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="10710">Enterobacteria phage lambda</organism>
    <external-identifiers>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02459</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P03697</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EXO_LAMBD</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.1.11.3</synonym>
      <synonym>red-alpha</synonym>
      <synonym>redX</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017035|Exonuclease
MTPDIILQRTGIDVRAVEQGDDAWHKLRLGVITASEVHNVIAKPRSGKKWPDMKMSYFHT
LLAEVCTGVAPEVNAKALAWGKQYENDARTLFEFTSGVNVTESPIIYRDESMRTACSPDG
LCSDGNGLELKCPFTSRDFMKFRLGGFEAIKSAYMAQVQYSMWVTRKNAWYFANYDPRMK
REGLHYVVIERDEKYMASFDEIVPEFIEKMDEALAEIGFVFGEQWR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0017036|Exonuclease (exo)
ATGACACCGGACATTATCCTGCAGCGTACCGGGATCGATGTGAGAGCTGTCGAACAGGGG
GATGATGCGTGGCACAAATTACGGCTCGGCGTCATCACCGCTTCAGAAGTTCACAACGTG
ATAGCAAAACCCCGCTCCGGAAAGAAGTGGCCTGACATGAAAATGTCCTACTTCCACACC
CTGCTTGCTGAGGTTTGCACCGGTGTGGCTCCGGAAGTTAACGCTAAAGCACTGGCCTGG
GGAAAACAGTACGAGAACGACGCCAGAACCCTGTTTGAATTCACTTCCGGCGTGAATGTT
ACTGAATCCCCGATCATCTATCGCGACGAAAGTATGCGTACCGCCTGCTCTCCCGATGGT
TTATGCAGTGACGGCAACGGCCTTGAACTGAAATGCCCGTTTACCTCCCGGGATTTCATG
AAGTTCCGGCTCGGTGGTTTCGAGGCCATAAAGTCAGCTTACATGGCCCAGGTGCAGTAC
AGCATGTGGGTGACGCGAAAAAATGCCTGGTACTTTGCCAACTATGACCCGCGTATGAAG
CGTGAAGGCCTGCATTATGTCGTGATTGAGCGGGATGAAAAGTACATGGCGAGTTTTGAC
GAGATCGTGCCGGAGTTCATCGAAAAAATGGACGAGGCACTGGCTGAAATTGGTTTTGTA
TTTGGGGAGCAATGGCGATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF09588</identifier>
        <name>YqaJ</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>exonuclease activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
